TY - STD TI - Cáncer recurrente de pulmón de células no pequeñas. [http://Cancer.gov/espanol/pdq/tratamiento/pulmon-celulas-no-pequenas] UR - http://Cancer.gov/espanol/pdq/tratamiento/pulmon-celulas-no-pequenas ID - ref1 ER - TY - JOUR AU - Ramalingam, S. PY - 2008 DA - 2008// TI - Systemic chemotherapy for advanced NSCLC: recent advances and future directions JO - The Oncologist VL - 13 UR - https://doi.org/10.1634/theoncologist.13-S1-5 DO - 10.1634/theoncologist.13-S1-5 ID - Ramalingam2008 ER - TY - JOUR AU - Manegold, C. PY - 2007 DA - 2007// TI - Randomized double blind multicenter phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy naïve patients with advanced or recurrent non-squamous NSCLC JO - J Clin Oncol VL - 25 ID - Manegold2007 ER - TY - CHAP AU - Shepherd, F. A. PY - 2003 DA - 2003// TI - Second line chemotherapy for NSCLC BT - Asco. Ed.Book ID - Shepherd2003 ER - TY - JOUR AU - Gridelli, C. PY - 2007 DA - 2007// TI - Erlotinib in NSCLC treatment: current status and future development JO - The Oncologist VL - 12 UR - https://doi.org/10.1634/theoncologist.12-7-840 DO - 10.1634/theoncologist.12-7-840 ID - Gridelli2007 ER - TY - JOUR AU - Shepherd, F. A. PY - 2005 DA - 2005// TI - Erlotinib in previously treated NSCLC JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa050753 DO - 10.1056/NEJMoa050753 ID - Shepherd2005 ER - TY - JOUR AU - Jackman, D. M. PY - 2007 DA - 2007// TI - Phase II clinical trial of Chemotherapy-Naïve patients ≥ 70 years of age treatment with erlotinib for advanced NSCLC JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.07.5754 DO - 10.1200/JCO.2006.07.5754 ID - Jackman2007 ER - TY - STD TI - NCCN: Practice guidelines in oncology (NSCLC – 13, 14) NSCLC -E 1–2 v.2.2008. ID - ref8 ER - TY - JOUR AU - Hanna, N. PY - 2004 DA - 2004// TI - Randomized phase III trial of pemetrexed vs. docetaxel in patients with NSCLC previously treated with chemotherapy JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.08.163 DO - 10.1200/JCO.2004.08.163 ID - Hanna2004 ER - TY - JOUR AU - Galimont-Collen, A. F. S. PY - 2007 DA - 2007// TI - Classification and management of skin, hair, nail and mucosal side-effects of EGFR inhibitors JO - Eur J Cancer VL - 43 UR - https://doi.org/10.1016/j.ejca.2006.11.016 DO - 10.1016/j.ejca.2006.11.016 ID - Galimont-Collen2007 ER - TY - JOUR AU - Segaert, S. PY - 2005 DA - 2005// TI - Clinical signs, pathophysiology and management of skin toxicity during therapy with EGFR inhibitors JO - Ann Oncol VL - 16 UR - https://doi.org/10.1093/annonc/mdi279 DO - 10.1093/annonc/mdi279 ID - Segaert2005 ER - TY - JOUR AU - Wacker, B. PY - 2007 DA - 2007// TI - Correlation between development of rash and efficacy in patients treated with EFGR tyrosine kinase inhibitor erlotinib in two large phase III studies JO - Clin Cancer Res VL - 13 UR - https://doi.org/10.1158/1078-0432.CCR-06-2610 DO - 10.1158/1078-0432.CCR-06-2610 ID - Wacker2007 ER - TY - JOUR AU - Tsao, M. S. PY - 2005 DA - 2005// TI - Erlotinib in lung cancer: molecular and clinical predictors of outcomes JO - N Eng J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa050736 DO - 10.1056/NEJMoa050736 ID - Tsao2005 ER - TY - JOUR AU - Gridelli, C. PY - 2007 DA - 2007// TI - Targeted therapies and NSCLC: new developments JO - Current Opinion in Oncology VL - 19 UR - https://doi.org/10.1097/CCO.0b013e328012a05b DO - 10.1097/CCO.0b013e328012a05b ID - Gridelli2007 ER - TY - JOUR AU - Thatcher, N. PY - 2007 DA - 2007// TI - The place of the targeted therapy in patient management of NSCLC JO - Lung cancer VL - 57 UR - https://doi.org/10.1016/S0169-5002(07)70423-3 DO - 10.1016/S0169-5002(07)70423-3 ID - Thatcher2007 ER - TY - JOUR AU - Siegel-Lakhel, W. S. PY - 2005 DA - 2005// TI - Current knowledge and future directions of the selective EGFRI erlotinib (Tarceva) and gefitinib (Iressa) JO - The Oncologist VL - 10 UR - https://doi.org/10.1634/theoncologist.10-8-579 DO - 10.1634/theoncologist.10-8-579 ID - Siegel-Lakhel2005 ER - TY - JOUR AU - Rubio-Terres, C. PY - 2006 DA - 2006// TI - Análisis farmaeconómico del tratamiento con erlotinib, docetaxel, pemetrexed o tratamiento de soporte en pacientes con CPNM avanzado previamente tratado con quimioterapia JO - Pharmaeconomics spanish research articles VL - 3 UR - https://doi.org/10.1007/BF03320917 DO - 10.1007/BF03320917 ID - Rubio-Terres2006 ER -